Sotalol Hydrochloride

HCID 66245CAS 959-24-0

기본 정보

표준 SMILES: CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl
InChIKey: VIDRYROWYFWGSY-UHFFFAOYSA-N
분자식: C12H21ClN2O3S
평균 분자량: 308.83 g/mol

개요

Sotalol hydrochloride is a hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. It has a role as a beta-adrenergic antagonist and an anti-arrhythmia drug. It contains a sotalol(1+).

이름 및 식별자

우선 이름: Sotalol Hydrochloride
IUPAC: N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;hydrochloride

이름 및 동의어

Sotalol hydrochloride959-24-0Sotalol HCLBetapaceBetapace AFSotacorSotalexSorineSotylizeBerlexMJ 1999Darob

이름 더 보기

Sotalol MonohydrochlorideHEC37C70XXIsopropylaminohydroxyethylmethanesulfonanilide hydrochloride4'-(1-Hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide monohydrochlorideNSC-337251NSC-760358DTXSID8021278N-Isopropyl-beta-(4-methanesulfonamidophenyl)ethanolamine hydrochloride

데이터베이스 식별자

CAS: 959-24-0
PubChem CID: 66245
ChEMBL: CHEMBL1700
ChEBI: CHEBI:9207
UNII: HEC37C70XX
EC Number: 213-496-0

물성

구조 계산 물성

극성 표면적: 86.8 Å²
수소 결합 공여자 수: 4
수소 결합 수용자 수: 5
회전 가능 결합 수: 6
무거운 원자 수: 19
형식 전하: 0
복잡도: 330

실험 및 물리화학적 성질

Solubility>46.3 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

FDA approved drugs -> Active ingredient

Collision Cross Section166.3 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

안전 및 규제

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 1.4% (1 of 73) of reports.

Warning

H315 (94.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 73 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Other Safety InformationIMAP assessments - Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-, monohydrochloride: Environment tier I assessment

Hazard Classes and CategoriesSkin Irrit. 2 (94.5%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sotalol hydrochloride

Ambiguous-DILI-concern

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

화학 및 산업

약리 정보

FDA Pharmacological Classification · 6건

SOTALOL HYDROCHLORIDE

Cardiac Rhythm Alteration [PE]; Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]

SOTALOL HYDROCHLORIDE TABLES AF

Adrenergic beta-Antagonists [MoA]; Antiarrhythmic [EPC]; Cardiac Rhythm Alteration [PE]

SOTALOL HYDROCHLORIDE TABLETS AF

Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]; Cardiac Rhythm Alteration [PE]

MeSH Pharmacological Classification · 3건

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.